What are the Phase 1 results?

Early results showed encouraging safety and clinical activity in patients who failed prior therapy.

How does this affect Eli Lilly's stock?

It highlights pipeline diversification beyond obesity drugs, but remains early-stage.

Eli Lilly Reports Promising JAK2 Inhibitor Data for Myelofibrosis

Eli Lilly (LLY) announced Phase 1 data for AJ1-11095, a first-in-class type II JAK2 inhibitor, in myelofibrosis patients. Early results show safety and activity in a difficult-to-treat population.

June 15, 2026

2 min read

Source: Simply Wall St.

Eli Lilly (NYSE:LLY) reported Phase 1 data for AJ1-11095, a first-in-class type II JAK2 inhibitor, in myelofibrosis patients. The AJX-101 study focused on individuals whose disease continued after prior type I JAK2 inhibitor treatment. Early results showed encouraging safety findings and clinical activity in this difficult to treat group.

The Product

AJ1-11095 is the first type II JAK2 inhibitor to be tested in humans. It targets patients who have failed current JAK2 inhibitors like ruxolitinib.

Pricing and Availability

No pricing or timeline for commercial launch has been announced, as the drug is still in Phase 1 trials.

Competition

The current market is dominated by ruxolitinib (Incyte/Novartis) and fedratinib (CTI Bio). AJ1-11095 could offer a new option for treatment-resistant patients.

Potential Impact on Company

This data helps diversify Eli Lilly's pipeline beyond obesity drugs and demonstrates strength in hematology. However, the path to market is still long.

Frequently Asked Questions

It is a first-in-class type II JAK2 inhibitor being tested for myelofibrosis.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.